Skip to main content

Table 3 The performance indicators of screening, stratified by the age, sex, and the brands of tests

From: Brand interchangeability of pepsinogen tests in the real-world setting after eradication of Helicobacter pylori: a community-based study

Brands of PG test Positive predictive value (%)* Detection rate (per 1000)*
Atrophic gastritis Intestinal metaplasia Atrophic gastritis Intestinal metaplasia
Test 1 Test 2 Test 1 + 2 Test 1 Test 2 Test 1 + 2 Test 1 Test 2 Test 1 + 2 Test 1 Test 2 Test 1 + 2
Male
 30–49 years 10.0 10.0 6.7 10.0 11.1 6.7 1.2 1.2 1.2 1.2 1.2 1.2
 ≥ 50 years 20.6 19.4 16.3 32.3 28.0 25.6 4.2 4.2 4.2 6.6 6.6 6.6
Subtotal 18.2 17.4 13.8 27.3 26.7 20.7 3.2 3.2 3.2 4.8 4.8 4.8
Female
 30–49 years 11.1 12.5 8.3 11.1 11.1 7.7 1.0 1.0 1.0 1.0 1.0 1.0
 ≥ 50 years 14.8 15.4 11.4 22.2 15.4 20.0 2.5 2.5 2.5 3.7 2.5 4.4
Subtotal 13.8 14.7 10.6 19.4 14.3 16.7 1.9 1.9 1.9 2.7 1.9 3.1
Both sexes
 30–49 years 10.5 11.1 7.4 10.5 11.1 7.1 1.1 1.1 1.1 1.1 1.1 1.1
 ≥ 50 years 18.0 17.7 14.1 27.9 24.2 23.1 3.4 3.4 3.4 5.2 4.6 5.5
Total 16.3 16.3 12.4 23.8 21.3 18.9 2.5 2.5 2.5 3.7 3.3 3.9
  1. PG = pepsinogen; Test 1 = GastroPanel (Biohit HealthCare, Helsinki, Finland); Test 2 = LZ-Test (Eiken Chemical Co., Ltd, Tokyo, Japan); Test 1 + 2 = two tests in parallel
  2. *Positive predictive value was defined as the number of participants with premalignant lesions/ the number of participants positive to PG tests having attended an upper endoscopy. Detection rate was defined as the number of participants with premalignant lesions detected/ the number of participants having received the PG testing
  3. None reaches the significant P level of < 0.05 in the comparison between Test 1 and Test 2